Pear Therapeutics

OverviewSuggest Edit

Pear Therapeutics, also referred to as Pear, is a company developing drug-software combination therapies to help people with mental and behavioral health issues. The company combines pharmaceutical therapy with software technology, such as digital applications and games. Pear has products at different stages of the development pipeline, including marketed products, across therapeutic areas, including mental health disorders, severe insomnia, and multiple sclerosis.

HQBoston, MA, US
Employee Ratings3.9

Latest Updates

Employees (est.) (Sept 2021)247(+3%)
Cybersecurity ratingAMore

Key People/Management at Pear Therapeutics

Corey McCann

Corey McCann

President , CEO , Director
Chris Guiffre

Chris Guiffre

Yuri Maricich

Yuri Maricich

Chief Medical Officer , Head of Development
Erin Brenner

Erin Brenner

Chief Product Development Officer
Julia Strandberg

Julia Strandberg

Chief Commercial Officer
Ronan O'Brien

Ronan O'Brien

General Counsel , Secretary
Show more

Pear Therapeutics Office Locations

Pear Therapeutics has offices in Boston and San Francisco
Boston, MA, US (HQ)
200 State St
San Francisco, CA, US
Providian Financial Building, 201 Mission St, San Francisco
Show all (2)

Pear Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Pear Therapeutics total Funding

$207.8 m

Pear Therapeutics latest funding size

$80 m

Time since last funding

10 months ago

Pear Therapeutics investors

Pear Therapeutics's latest funding round in December 2020 was reported to be $80 m. In total, Pear Therapeutics has raised $207.8 m
Show all financial metrics

Pear Therapeutics Operating Metrics

Aug, 2019

Discovery Stage Products (Internal)


Discovery Stage Products (Partnered)


POC Stage Products (Internal)


POC Stage Products (Partnered)

Show all operating metrics

Pear Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Pear Therapeutics Online and Social Media Presence

Embed Graph

Pear Therapeutics Company Culture

  • CEO Rating



  • Compensation



Learn more on Comparably

Pear Therapeutics News and Updates

Softbank-Backed Pear Therapeutics Plans To Go Public In $1.6 Billion SPAC Deal

The prescription digital therapeutics company, which has three FDA authorized apps, is estimating only $4 million in revenue in 2021.

Pear Therapeutics is going public in a $1.6 billion SPAC deal. Its projected revenue reveals just how hard it is to make money with a doctor-prescribed app.

Summary List PlacementOne of the first companies to develop an app that doctors can prescribe to patients is going public at a $1.6 billion valuation.  Pear Therapeutics, which is based in Boston, is merging with special purpose acquisition company Thimble Point Acquisition Corp., the duo announce…

Pear Therapeutics raises $80M in push for reimbursement

Pear Therapeutics raised $80 million in funding, which it plans to use as part of a push for coverage of its digital therapeutics

Virtual Reality in Medicine and Healthcare Market Aims to Expand at Double Digit Growth Rate | XRHealth, Pear Therapeutics, Firsthand Technology

The latest edition of this report you will be entitled to receive additional chapter / commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry Posted via Industry Today. Follow us on Twitter @IndustryToday

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

HOLZKIRCHEN, January 7, 2018 - Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-O, cleared by the US Food and Drug Administration (FDA) in December, is immediately available.

Pear Therapeutics receives $64 mln in Temasek-led funding

Privately held Pear Therapeutics said on Friday it raised $64 million from investors, including Singapore's Temasek Holdings, weeks after its mobile app for treating patients with substance use disorder was launched.
Show more

Pear Therapeutics Blogs

Pear Therapeutics Announces Additional Coverage Decisions and Formulary Adoption of its Prescription Digital Therapeutics

Pear is the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, with three FDA-authorized PDTs  More than 30 organizations now provide access to Pear’s PDTs by either listing on formulary, as a covered benefit, or purchasing products in bulk As…

Pear Therapeutics to Participate in the DTx East 2021 Conference

Boston and San Francisco, September 21, 2021 – Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today announced that Julia Strandberg, Chief Commercial Officer, will participate in a panel discussion at the fourt…

Pear Therapeutics Announces Publication of Real-World Data Showing Improved Clinical Outcomes with a Subsequent Prescription of reSET-O® for Patients with Opioid Use Disorder

reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD) This new analysis examined real-world health outcome data from over 3,000 patients with OUD treated for 12 weeks with reSET-O, and over 600 patients treated for 24 week…

Pear and Thimble Point Announce Nominees to Board of Directors

Kirthiga Reddy, Partner at SoftBank Investment Advisers, and Alison Bauerlein, co-founder, Chief Financial Officer and Executive Vice President of Finance at Inogen, are nominees to become directors of Thimble Point Acquisition Corp. (Nasdaq: THMA), which will be renamed Pear Holdings Corp. upon the…

Pear Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Boston and San Francisco, September 7, 2021 – Pear Therapeutics, Inc. today announced management’s participation in the Morgan Stanley 19th Annual Global Healthcare Conference. Corey McCann, M.D., Ph.D., President and CEO, will participate in a fireside chat on Friday, September 10 at 5:00 p.m. East…

Pear Therapeutics Announces Publication of Cost-Utility Data Showing Quality of Life and Cost Reduction with reSET-O® for the Treatment of Opioid Use Disorder

reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD). Consistent with prior analyses, new analysis shows reSET-O in conjunction with treatment-as-usual (TAU: buprenorphine + clinician) to be more effective and less costly co…
Show more

Pear Therapeutics Frequently Asked Questions

  • When was Pear Therapeutics founded?

    Pear Therapeutics was founded in 2013.

  • Who are Pear Therapeutics key executives?

    Pear Therapeutics's key executives are Corey McCann, Chris Guiffre and Yuri Maricich.

  • How many employees does Pear Therapeutics have?

    Pear Therapeutics has 247 employees.

  • Who are Pear Therapeutics competitors?

    Competitors of Pear Therapeutics include Curalie, Hygieia and Jointfully.

  • Where is Pear Therapeutics headquarters?

    Pear Therapeutics headquarters is located at 200 State St, Boston.

  • Where are Pear Therapeutics offices?

    Pear Therapeutics has offices in Boston and San Francisco.

  • How many offices does Pear Therapeutics have?

    Pear Therapeutics has 2 offices.